Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
medmix AG is a Swiss-based global leader in designing, developing, manufacturing, and delivering high-precision delivery devices and fluid mixing technologies. The company operates across two primary segments: Healthcare, encompassing Dental, Drug Delivery, and Surgery, and Consumer & Industrial, including Industry and Beauty applications. In Healthcare, it provides products like mixing tips, cartridges for prosthetics, restorations, anesthetics, and aesthetics; drug delivery devices for fertility drugs, growth hormones, diabetes, osteoporosis, and rare diseases; and surgical tools for bone tissue injection and hemostatic sealants. The Consumer & Industrial segment supplies dispensers, cartridges, mixers for two-component adhesives in construction, transportation (automotive, railways, aerospace), electronics, infrastructure, and DIY, alongside micro-brushes for makeup and skincare. Brands include MIXPAC, transcodent, Haselmeier, Geka, and others. With over 900 active patents, 14 production sites worldwide, and approximately 2,700 employees, medmix drives innovation in these markets, stemming from a 2021 spin-off from Sulzer.
Operating margin is thin at 6.21%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 7.4% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 30% versus the prior year, cash generation momentum has weakened. Net debt of CHF 240M represents 9.0x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
CHF 448M
▼ -7.4% YoY
Net Income (TTM)
CHF 7M
▲ +212.7% YoY
Op. Margin
6.21%
▲ +2.5pp YoY
ROIC
2.86%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
CHF 27M
▼ -29.9% YoY
Op. Cash Flow (TTM)
CHF 61M
▲ +26.1% YoY
Net Debt
CHF 240M
Cash & Equiv.
CHF 91M
3Y CAGR: -2.1%
3Y CAGR: +43.7%
Continue Research